Filings & corporate actions
36 results filed
CSVNext results · Q2 FY27
Expected 21 Oct 2026 – 14 Nov 2026
Estimate: filed 21–45 days after quarter end, last 5 times
Dividend
₹3.00 per share · last 18 Aug 2021
2026
- 23 JulresultsResults · Q1 FY27 · consolidated and standalone-6.1%NSE
- 20 JulshareholdingShareholding · 30 Jun 2026-0.1%NSE
- 22 MayshareholdingShareholding · 15 May 2026-2.9%NSE
- 15 MayresultsResults · Q4 FY26 · consolidated and standalone-3.2%NSE
- 20 AprshareholdingShareholding · 31 Mar 2026-1.5%NSE
- 6 FebresultsResults · Q3 FY26 · consolidated and standalone+1.7%NSE
- 20 JanshareholdingShareholding · 31 Dec 2025-2.3%NSE
Reaction to results · all yearsrose on day 0 in 11 of 33 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 23 Jul 2026 | -6.1% | -1.9% | +17.8% | 2.1× |
| Q4 FY26 | 15 May 2026 | -3.2% | -4.4% | +1.6% | 1.5× |
| Q3 FY26 | 6 Feb 2026 | +1.7% | +3.4% | -4.5% | 7.4× |
| Q2 FY26 | 6 Nov 2025 | -8.8% | -7.5% | -10.9% | 6.5× |
| Q1 FY26 | 25 Jul 2025 | -5.7% | -11.6% | -12.8% | 1.5× |
| Q4 FY25 | 15 May 2025 | -7.9% | -8.1% | -2.6% | 6.0× |
| Q3 FY25 | 24 Jan 2025 | -10.0% | -18.0% | -21.1% | 2.2× |
| Q2 FY25 | 21 Oct 2024 | -5.0% | -6.0% | -7.4% | 2.3× |
| Q1 FY25 | 22 Jul 2024 | +5.0% | +6.2% | +21.1% | 0.6× |
| Q4 FY24 | 29 May 2024 | -2.9% | -1.0% | +27.0% | 1.1× |
| Q3 FY24 | 14 Feb 2024 | +8.5% | +34.0% | +8.3% | 6.4× |
| Q2 FY24 | 14 Nov 2023 | -2.4% | -3.5% | -3.8% | 0.5× |
| Q1 FY24 | 14 Aug 2023 | -1.3% | +1.1% | -0.1% | 1.7× |
| Q4 FY23 | 12 May 2023 | -6.4% | -12.0% | -13.3% | 1.7× |
| Q3 FY23 | 25 Jan 2023 | -4.8% | -9.4% | -16.5% | 1.6× |
| Q2 FY23 | 10 Nov 2022 | -2.6% | +0.9% | -0.8% | 0.8× |
| Q1 FY23 | 4 Aug 2022 | -2.9% | -1.2% | +12.9% | 0.7× |
| Q4 FY22 | 29 Apr 2022 | -20.0% | -29.7% | -36.0% | 8.2× |
| Q3 FY22 | 9 Feb 2022 | -20.0% | -24.1% | -23.1% | 1.2× |
| Q2 FY22 | 12 Nov 2021 | -10.1% | -19.1% | -7.0% | 7.4× |
| Q1 FY22 | 5 Aug 2021 | +2.0% | +0.8% | -4.2% | 2.1× |
| Q4 FY21 | 7 May 2021 | -4.9% | +3.5% | +4.2% | 1.3× |
| Q3 FY21 | 4 Feb 2021 | -2.1% | +9.8% | -11.1% | 0.6× |
| Q2 FY21 | 30 Oct 2020 | -5.0% | -4.8% | +4.7% | 0.5× |
| Q1 FY21 | 3 Aug 2020 | +19.0% | +28.7% | +22.5% | 13.5× |
| Q4 FY20 | 8 May 2020 | -6.6% | -5.6% | +9.1% | 2.7× |
| Q3 FY20 | 10 Feb 2020 | +0.6% | +21.0% | -15.2% | 2.0× |
| Q2 FY20 | 13 Jan 2020 | +3.4% | +1.3% | +26.4% | 1.6× |
| Q1 FY20 | 13 Aug 2019 | +0.7% | +2.7% | +11.8% | 4.8× |
| Q4 FY19 | 17 May 2019 | -3.8% | -7.3% | +0.3% | 0.5× |
| Q3 FY19 | 6 Feb 2019 | +1.9% | +1.6% | +2.6% | 2.1× |
| Q2 FY19 | 9 Nov 2018 | +4.4% | -0.4% | -12.3% | 2.4× |
| Q1 FY19 | 8 Aug 2018 | +5.0% | +34.0% | +51.2% | 0.2× |
| Average | -2.7% | -0.8% | +0.6% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+19.6%
Profit YoY+55.0%
Interest cost YoY-14.2%
Revenue QoQ-1.5%
Profit QoQ+69.9%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | +3.5% | -0.8% | +4.7% | -3.1% | +1.1% | +0.2% |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen682.00
Day range668.10 – 689.70
52-week range422.00 – 774.00
From 52w high-11.8%
RSI (14)48.1
ATR (14)35.95
Volume1.97L
Avg volume (20D)5.79L
Rel volume0.34×
Volatility (1Y)44.4%
Turnover₹13.4Cr
SMA 50 / 200625.10 / 548.18
Delivery percentage
Latest · 6 Oct 202639.2%
20-day avg38.5%
1-year avg45.3%
Percentile (own history)23rd
Range8.4–100.0%
Sessions1,731
Over the last 20 sessions SOLARA settled 38.5% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 45.3%, so recent sessions are running 6.8 points lower than usual. The latest session ranks higher than 23% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +0.85% | -7.29% | +8.38% | +21.83% | +43.38% | +10.95% |
Valuation
CSVMarket cap₹3,282 Cr
P/E (TTM)—
EPS (TTM)-0.34
Shares outstanding4.81Cr
Listed27 Jun 2018
Ownership
CSVPromoter41.93%
Promoter Δ QoQ-0.07 pp
Public58.07%
FII11.52%
DII3.74%
Pledged37.11%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 313.5 | 349.0 | 387.3 | 381.6 |
| YoY chg | -9.6% | +16.2% | +41.9% | +19.6% |
| Net profit (₹ Cr) | (10.1) | (17.4) | 9.6 | 16.3 |
| YoY chg | -226.1% | -315.5% | — | +55.0% |
| Net margin | -3.2% | -5.0% | 2.5% | 4.3% |
| EPS | -2.36 | -3.98 | 2.20 | 3.52 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 41.93% · public 58.07%2021-062026-06
- Promoter
- Public and others
- Promoter
- 41.93%
- Public
- 58.07%
- Promoter change
- -0.07 pp
- Filed
- 20 Jul 2026
- FII
- 11.52%
- DII
- 3.74%
- Promoter pledged
- 37.11%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 425.2 | 248.7 | 299.4 | 363.5 | 347.0 | 300.3 | 273.0 | 319.2 | 313.5 | 349.0 | 387.3 | 381.6 | |
| Other income | 1.2 | 0.5 | 1.7 | 0.6 | 0.3 | 1.5 | 6.0 | 1.0 | 0.5 | 0.0 | 4.7 | 2.7 | |
| Total income | 426.4 | 249.2 | 301.1 | 364.1 | 347.3 | 301.8 | 279.0 | 320.1 | 314.0 | 349.0 | 392.0 | 384.3 | |
| Total expenses | 438.3 | 461.8 | 345.6 | 377.5 | 339.3 | 293.7 | 281.1 | 309.6 | 324.1 | 359.7 | 383.2 | 368.0 | |
| └ Finance costs | 24.4 | 25.4 | 30.7 | 30.9 | 28.3 | 26.5 | 29.1 | 23.9 | 20.8 | 22.5 | 27.6 | 21.6 | |
| └ Depreciation | 26.2 | 26.0 | 25.3 | 25.1 | 25.3 | 24.5 | 24.3 | 23.6 | 24.5 | 25.6 | 26.0 | 26.7 | |
| Profit before tax | (17.1) | (275.3) | (166.7) | (13.5) | 8.0 | 8.1 | (2.1) | 10.5 | (10.1) | (17.4) | 9.6 | 16.3 | |
| Tax expense | 0.0 | 0.0 | 88.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net profit | (17.1) | (275.3) | (255.5) | (13.5) | 8.0 | 8.1 | (2.1) | 10.5 | (10.1) | (17.4) | 9.6 | 16.3 | |
| EPS | -4.77 | -76.49 | -70.93 | -3.50 | 2.54 | 2.03 | -0.93 | 2.46 | -2.36 | -3.98 | 2.20 | 3.52 | |
| Net margin | -4.01% | -110.70% | -85.31% | -3.70% | 2.31% | 2.69% | -0.77% | 3.30% | -3.22% | -4.99% | 2.48% | 4.27% | |
| PBT margin | -4.01% | -110.70% | -55.66% | -3.70% | 2.31% | 2.69% | -0.77% | 3.30% | -3.22% | -4.99% | 2.48% | 4.27% | |
| Tax rate | — | — | — | — | 0.00% | 0.00% | — | 0.00% | — | — | 0.00% | 0.00% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 23 Jul 2026.
SOLARA at a glance
- SOLARA closed at ₹682.65 on 6 Oct 2026, +0.85% on the day, +10.9% over one year, 11.8% below its 52-week high of ₹774.
- Delivery was 39.2% of traded quantity on 6 Oct 2026, the 23rd percentile of its own 1,731 sessions with a reading (20-session average 38.5%, 1-year average 45.3%).
- Market capitalisation is ₹3,282 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-0.34).
- Q1 FY27 results (consolidated, filed 23 Jul 2026): revenue ₹382 crore (+19.6% year on year), net profit ₹16 crore (+55.0%); the price moved -6.1% on the first session after.
- Promoters held 41.93% at 30 Jun 2026, down 0.07 percentage points on the previous filing, with 37.11% of promoter shares pledged.
- Q2 FY27 results are expected between 21 Oct 2026 and 14 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE624Z01016
SeriesEQ
Listed27 Jun 2018
History from27 Jun 2018
Sessions2,046
Turnover rank#534
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE